Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

200971 citationsJournal Articlebronze Open Access

Authors

All casopitant regimens studied were more effective than the control regimen. Casopitant was generally well tolerated.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 27, Issue 32, pp. 5363-5369

Field-Weighted Citation Impact: 11.48